qi.yang管理团队
-
【IND enabling】TYK2/JAK1 Dual Inhibitor Breaks New Ground in CNS Drug Development【Product for Licensing】
Growing evidence suggests that inflammatory responses play a pivotal role in the pathogene…
-
药时代BD项目 | 每日一次口服JAK1/TYK2双靶点透脑小分子抑制剂
TYK2/JAK1双重抑制剂 首次从自免杀入神经系统疾病 越来越多的研究表明，炎症反应在阿尔茨海默病（AD）和帕金森病（PD）等神经退行性疾病的发病机制中扮演着关键角…
-
【IND enabling】Once daily oral brain-penetrant dual JAK1/TYK2 inhibitor with better efficacy and safety【Product for Licensing】
Project ID：DT-202500428-041 Product Brief Summary More highlights Contact us: For any ques…
-
【pre-PCC】A Potential Best-in-Class CDK2 Inhibitor with Better Selectivity, Better Efficacy and Superior PK【Product for Licensing】
Project ID：DT-202500410-038 Product Brief Summary More highlights Contact us: For any ques…
-
【Phase I】First-in-class Phase I Dual-target Oral Molecular Glue for Hematologic Malignancies with Broad-spectrum Activity and Better Safety Profile 【Product for Licensing】
Project ID：DT-202500410-037 Product Brief Summary More highlights Contact us: For any ques…
-
【Preclinical】A safer and more effective small-molecule regulator of miR-124 for IBD treatment 【Product for Licensing】
Project ID：BP-20240718-OR-77 Product Brief Summary More highlights Contact us…
-
High Binding Affinities and Potent Anti-tumor Efficacy Nectin4-CD137 BsAb 【Product for Licensing】
Project ID：BP-20240318-OR-029 Product Brief Summary Key Advantages: It demonstrated potent…
-
A Highly Differentiated IL-2- Fc-IFN-α Fusion Protein for Cancer Combination Therapies 【Product for Licensing】
If interested, please contact DrugTimes BD Team at BD@drugtimes.cn. Many thanks!
-
A FIC Her2xCD47xCD16a Tri-specific Antibody for Treating Her2 High and Low or Negative Cancers 【Product for Licensing】
If interested, please contact DrugTimes BD Team at BD@drugtimes.cn. Many thanks!
